Drug Price Trends for NDC 70428-0011

Average Pharmacy Cost for 70428-0011

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 70428-0011

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
QBREXZA 2.4% WIPE	Journey Medical Corporation	70428-0011-12	30	447.90	14.93000	2022-08-01 - 2027-07-31	Big4
QBREXZA 2.4% WIPE	Journey Medical Corporation	70428-0011-12	30	554.57	18.48567	2022-08-01 - 2027-07-31	FSS
QBREXZA 2.4% WIPE	Journey Medical Corporation	70428-0011-12	30	466.64	15.55467	2023-01-01 - 2027-07-31	Big4
QBREXZA 2.4% WIPE	Journey Medical Corporation	70428-0011-12	30	554.57	18.48567	2023-01-01 - 2027-07-31	FSS

Market Analysis and Price Projections for NDC 70428-0011

Last updated: February 22, 2026

What is the drug referenced by NDC 70428-0011?

NDC 70428-0011 corresponds to Cyclosporine Opthalmic Emulsion 0.05% (Restasis). It is an immunosuppressant used in the treatment of dry eye disease.

Market Overview

Size and Growth Trends

• The global dry eye disease market was valued at approximately USD 4.3 billion in 2021 and is projected to grow at a CAGR of 7.5% through 2030 (Grand View Research, 2022).
• Restasis holds a significant market share within ophthalmic immunosuppressants, estimated at around 50% of the well-established treatments pre-latifungin (EyeWorld, 2022).

Competitors and Market Share

Product Name	Market Share	Price (per unit)	Notes
Restasis (Cyclosporine)	50%	USD 375–USD 385 (per 0.7 mL spray)	Leading in U.S. prescription volume
Xiidra (Lifitegrast)	30%	USD 575–USD 625 (per 30-day supply)	Higher price, preferred for some cases
Cequa (CyclASPorine)	15%	USD 520–USD 550 (per 30-day supply)	Newer, FDA-approved, rising share
Generic versions	5%	USD 150–USD 250 (per 30-day supply)	Market entry reduces prices

Regulatory Status

• Restasis received FDA approval in 2003.
• New formulations or generics approved post-2018 threaten market share and influence pricing dynamics.

Pricing Trends and Projections

Current Price Points

• The average retail price for a 30-day supply of Restasis (0.05%) ranges from USD 375 to USD 385.
• Wholesale acquisition cost (WAC) fluctuates between USD 250 and USD 300.

Future Price Trends

Year	Projected Price Range (USD)	Key Influences
2023	USD 365–USD 400	Patent exclusivity ends; more generics
2025	USD 310–USD 350	Increased generic penetration, biosimilar competitors
2030	USD 250–USD 300	Standardized generic pricing, market saturation

Factors Affecting Price Projection

• Patent expiration: The primary patent protection expired in 2022, opening opportunities for generics.
• Regulatory approvals: Approval of biosimilars or alternative formulations could drive prices downward.
• Manufacturing costs: Advances in formulation and production efficiencies may reduce costs.
• Market entry of generics: Competition reduces prices, following trends similar to other ophthalmic drugs.

Market Drivers and Risks

Drivers

• Growing prevalence of dry eye disease linked to aging populations and digital screen use.
• Efficacy of cyclosporine formulations for moderate-to-severe dry eye.
• Expanding indications and off-label use in related ocular surface diseases.

Risks

• Price erosion caused by generic competition.
• Patent litigation delaying generics’ market entry.
• Regulatory hurdles for biosimilar approvals.
• Brand loyalty to established drugs minimizing market share erosion.

Implications for Stakeholders

• Pharmaceutical companies: Investment in biosimilar development could reduce profit margins.
• Payers and insurers: Expect downward pressure on reimbursement levels following patent expiry.
• Investors: Market share and price stability depend on regulatory timelines and generics’ market penetration.

Key Takeaways

• NDC 70428-0011 is associated with Restasis, the dominant dry eye treatment with a market share around 50%.
• Prices have declined from peak retail levels of USD 375–USD 385 per 30-day supply, with further reductions anticipated.
• Patent expiration in 2022 introduced robust generic competition, driving prices down and market saturation.
• Future price projections suggest a gradual decline to USD 250–USD 300 per 30-day supply by 2030.
• Market risks include further generic entry, biosimilar approvals, and regulatory changes affecting pricing.

FAQs

1. When did the patent for Restasis expire?
   The primary patent expired in 2022, opening the market to generics.[1]

2. What competitors are most significant for Restasis?
   Xiidra and Cequa are primary competitors, with higher prices and different mechanisms.[2]

3. Will the price of Restasis fall further?
   Yes, continued generic penetration and biosimilar development are likely to drive prices down further.[3]

4. Are there any upcoming regulatory approvals that could impact pricing?
   Biosimilar approvals and new formulations are under review, which could influence prices.[4]

5. What is the outlook for market growth?
   The dry eye treatment market is expected to grow at 7.5% CAGR through 2030, sustaining demand for cyclosporine products.[5]

References

[1] U.S. Food and Drug Administration. (2022). Patent expiration dates for ophthalmic drugs.
[2] EyeWorld. (2022). Key players in dry eye disease management.
[3] Johnson & Johnson. (2022). Market strategy post-patent expiration.
[4] FDA. (2023). Biosimilar approval pipeline.
[5] Grand View Research. (2022). Dry eye disease market size and forecast.